Receive our newsletter – data, insights and analysis delivered to you
  1. Digital Disruption
April 9, 2019updated 10 Apr 2019 2:14pm

Deep Lens to advance AI trial recruitment technology

US-based Deep Lens has raised funds in a series A round to advance its artificial intelligence (AI) pathology platform, VIPER, which is intended to drive clinical trial recruitment at the diagnosis stage.

The $14m financing round was led by Northpond Ventures and joined by Rev1 Ventures, Sierra Ventures and Tamarind-Hill Partners. This brings the company’s total funding support to $17.5m.

Deep Lens will use the fresh funds to further develop its AI and platform capabilities, as well as scale its service, sales and marketing network to improve access to the trial recruitment technology.

Deep Lens co-founder and CEO Dave Billiter said: “This Series A financing is further validation of the value of our industry-changing approach to digital pathology in delivering the right cancer diagnoses faster and accelerating oncology trial recruitment and timelines.”

Powered by AI, VIPER uses advanced pathology workflows for peer-to-peer alliance and patient identification in clinical trials. It is meant to deliver quick and accurate information on patient eligibility for the studies.

As the platform identifies patients at the time of diagnosis, it is expected to accelerate enrolment and potentially reduce the trial duration.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Originally designed for research use, the technology was utilised as the de-facto platform in certain oncology studies. Deep Lens later started commercialising the platform.

Deep Lens co-founder and chief scientist TJ Bowen said: “In the past year we have successfully launched our industry leading platform, VIPER, to the pathology industry at-large, we have integrated deep learning (AI) and we have made VIPER available free-of-charge to pathology groups worldwide as we work to identify patients at the time of diagnosis for available clinical trials.”

Last month, Deep Lens partnered with Worldwide Clinical Trials to fast-track enrolment in oncology trials using the VIPER digital pathology platform.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU